Gilead Sciences (GILD) 70.65 $GILD
Final Glance: Biotechnology companies
AP - 1 hr 39 mins ago
NEW YORK (AP) ' Shares of some top biotechnology companies were up at the close of trading:
Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 09, 11:46AM CDT
Last week saw a couple of positive FDA panel votes as well as some disappointing data on experimental drugs.
Shares of GILD Down 11.4% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Apr 09, 9:21AM CDT
SmarTrend identified a Downtrend for Gilead Sciences (NASDAQ:GILD) on March 13th, 2014 at $79.02. In approximately 4 weeks, Gilead Sciences has returned 11.41% as of today's recent price of $70.00.
Why Enanta Pharmaceuticals, Inc. Should Be on Your Watchlist
George Budwell, The Motley Fool - Motley Fool - Wed Apr 09, 8:30AM CDT
The next-generation hepatitis C drug race is rapidly coming to a head with Gilead Sciences ' regulatory filing of its all-oral, once-daily combo pill of Sovaldi plus ledipasvir and the anticipated filing of a New Drug Application for AbbVie and ...
Today's Top Health Care Stories: Intuitive Surgical, Aegerion, and Gilead Sciences
Leo Sun, The Motley Fool - Motley Fool - Wed Apr 09, 8:25AM CDT
Lets take a look at three stocks -- Intuitive Surgical , Aegerion , and Gilead Sciences -- which could cause a lot of market buzz across the health care sector this Wednesday morning. Intuitive Surgical's gloomy first quarter...
Clinical Trial Results Presentation and Publication, and Upcoming Exhibit - Analyst Notes on Gilead Sciences, Agios, Mindray, BG Medicine, and Ultragenyx
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), Mindray Medical International Limited (NYSE: MR), BG Medicine, Inc. (NASDAQ: BGMD), and Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Global Pontine Glioma Clinical Trials Review, H1, 2014
M2 - Wed Apr 09, 3:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rnkk47/pontine_glioma) has announced the addition of the "Pontine Glioma Global Clinical Trials Review, H1, 2014" report to their offering. Pontine Glioma Global Clinical Trials Review, H1, 2014" provides data on the Pontine Glioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pontine Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pontine Glioma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Pontine Glioma Therapeutics Clinical Trials - Oncoscience AG - Gilead Sciences, Inc. - National Cancer Institute - Children's Oncology Group - Children's Cancer and Leukaemia Group - Cancer Research UK - The University of Texas M. D. Anderson Cancer Center - Sidney Kimmel Comprehensive Cancer Center - Weill Cornell Medical College - Hadassah Medical Organization For more information visit http://www.researchandmarkets.com/research/rn...ine_glioma
Why Gilead Sciences, AbbVie Inc., and Biogen Idec Are Today's 3 Worst Stocks
John Divine, The Motley Fool - Motley Fool - Tue Apr 08, 7:05PM CDT
Eight in 10 sectors and nearly two out of every three stocks finished as winners on Tuesday. Well-versed pessimists know the implications of that: two in 10 sectors were big, fat losers today, and more than one in three stocks ended more loathed than...
Most active Nasdaq-traded stocks
AP - Tue Apr 08, 5:29PM CDT
NEW YORK (AP) ' A look at Nasdaq 10 most-active stocks at the close of trading:
Pipeline Update from Idenix - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 3:55PM CDT
Idenix's nucleotide polymerase inhibitor candidate, IDX21437, showed potent antiviral activity in patients suffering from hepatitis C virus (HCV) infection.
Watch for Gilead Sciences to Potentially Rebound After Falling 3.07% Yesterday
Comtex SmarTrend(R) - Tue Apr 08, 3:41PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $69.28 to a high of $71.71. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $70.72 on volume of 25.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Nike Sprints Higher as the Dow Dips Again
Dan Carroll, The Motley Fool - Motley Fool - Tue Apr 08, 1:39PM CDT
While stocks have bounced back from yesterday's big losses as the markets approach earnings season again, one index is heading down again. As of 2:35 p.m. EDT, the Dow Jones Industrial Average was just under breakeven, with blue-chip member stocks...
Midday Glance: Biotechnology companies
AP - Tue Apr 08, 12:16PM CDT
NEW YORK (AP) ' Shares of some top biotechnology companies are mixed at 1 p.m.:
FDA Target Date for Gilead's HCV Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 10:30AM CDT
Gilead is looking to bring a fixed-dose combination of Sovaldi and ledipasvir into the market for treating HCV.
Healthcare Investors Suffering Losses While Drug-Pricing War Rages
at The Street - Tue Apr 08, 10:23AM CDT
The latest salvo was lobbed Tuesday by pharmacy benefits manager Express Scripts against Gilead Sciences and its $1,000-per-day hepatitis C pill Sovaldi. Express Scripts says the U.S. healthcare system can't afford Sovaldi so it wants to form a...
Jim Cramer's Stop Trading: GILD ESRX
at The Street - Tue Apr 08, 9:59AM CDT
In the battle between Gilead and Express Scripts over the cost of hepatitis C pill Sovaldi, Gilead wins, Cramer asserts.
Early Glance: Biotechnology companies
AP - Tue Apr 08, 9:43AM CDT
NEW YORK (AP) ' Shares of some top biotechnology companies are mixed at 10 a.m.:
Final Glance: Biotechnology companies
AP - 1 hr 39 mins ago
NEW YORK (AP) ' Shares of some top biotechnology companies were up at the close of trading:
Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 09, 11:46AM CDT
Last week saw a couple of positive FDA panel votes as well as some disappointing data on experimental drugs.
Shares of GILD Down 11.4% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Apr 09, 9:21AM CDT
SmarTrend identified a Downtrend for Gilead Sciences (NASDAQ:GILD) on March 13th, 2014 at $79.02. In approximately 4 weeks, Gilead Sciences has returned 11.41% as of today's recent price of $70.00.
Why Enanta Pharmaceuticals, Inc. Should Be on Your Watchlist
George Budwell, The Motley Fool - Motley Fool - Wed Apr 09, 8:30AM CDT
The next-generation hepatitis C drug race is rapidly coming to a head with Gilead Sciences ' regulatory filing of its all-oral, once-daily combo pill of Sovaldi plus ledipasvir and the anticipated filing of a New Drug Application for AbbVie and ...
Today's Top Health Care Stories: Intuitive Surgical, Aegerion, and Gilead Sciences
Leo Sun, The Motley Fool - Motley Fool - Wed Apr 09, 8:25AM CDT
Lets take a look at three stocks -- Intuitive Surgical , Aegerion , and Gilead Sciences -- which could cause a lot of market buzz across the health care sector this Wednesday morning. Intuitive Surgical's gloomy first quarter...
Clinical Trial Results Presentation and Publication, and Upcoming Exhibit - Analyst Notes on Gilead Sciences, Agios, Mindray, BG Medicine, and Ultragenyx
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), Mindray Medical International Limited (NYSE: MR), BG Medicine, Inc. (NASDAQ: BGMD), and Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Global Pontine Glioma Clinical Trials Review, H1, 2014
M2 - Wed Apr 09, 3:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rnkk47/pontine_glioma) has announced the addition of the "Pontine Glioma Global Clinical Trials Review, H1, 2014" report to their offering. Pontine Glioma Global Clinical Trials Review, H1, 2014" provides data on the Pontine Glioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pontine Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pontine Glioma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Pontine Glioma Therapeutics Clinical Trials - Oncoscience AG - Gilead Sciences, Inc. - National Cancer Institute - Children's Oncology Group - Children's Cancer and Leukaemia Group - Cancer Research UK - The University of Texas M. D. Anderson Cancer Center - Sidney Kimmel Comprehensive Cancer Center - Weill Cornell Medical College - Hadassah Medical Organization For more information visit http://www.researchandmarkets.com/research/rn...ine_glioma
Why Gilead Sciences, AbbVie Inc., and Biogen Idec Are Today's 3 Worst Stocks
John Divine, The Motley Fool - Motley Fool - Tue Apr 08, 7:05PM CDT
Eight in 10 sectors and nearly two out of every three stocks finished as winners on Tuesday. Well-versed pessimists know the implications of that: two in 10 sectors were big, fat losers today, and more than one in three stocks ended more loathed than...
Most active Nasdaq-traded stocks
AP - Tue Apr 08, 5:29PM CDT
NEW YORK (AP) ' A look at Nasdaq 10 most-active stocks at the close of trading:
Pipeline Update from Idenix - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 3:55PM CDT
Idenix's nucleotide polymerase inhibitor candidate, IDX21437, showed potent antiviral activity in patients suffering from hepatitis C virus (HCV) infection.
Watch for Gilead Sciences to Potentially Rebound After Falling 3.07% Yesterday
Comtex SmarTrend(R) - Tue Apr 08, 3:41PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $69.28 to a high of $71.71. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $70.72 on volume of 25.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Nike Sprints Higher as the Dow Dips Again
Dan Carroll, The Motley Fool - Motley Fool - Tue Apr 08, 1:39PM CDT
While stocks have bounced back from yesterday's big losses as the markets approach earnings season again, one index is heading down again. As of 2:35 p.m. EDT, the Dow Jones Industrial Average was just under breakeven, with blue-chip member stocks...
Midday Glance: Biotechnology companies
AP - Tue Apr 08, 12:16PM CDT
NEW YORK (AP) ' Shares of some top biotechnology companies are mixed at 1 p.m.:
FDA Target Date for Gilead's HCV Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 10:30AM CDT
Gilead is looking to bring a fixed-dose combination of Sovaldi and ledipasvir into the market for treating HCV.
Healthcare Investors Suffering Losses While Drug-Pricing War Rages
at The Street - Tue Apr 08, 10:23AM CDT
The latest salvo was lobbed Tuesday by pharmacy benefits manager Express Scripts against Gilead Sciences and its $1,000-per-day hepatitis C pill Sovaldi. Express Scripts says the U.S. healthcare system can't afford Sovaldi so it wants to form a...
Jim Cramer's Stop Trading: GILD ESRX
at The Street - Tue Apr 08, 9:59AM CDT
In the battle between Gilead and Express Scripts over the cost of hepatitis C pill Sovaldi, Gilead wins, Cramer asserts.
Early Glance: Biotechnology companies
AP - Tue Apr 08, 9:43AM CDT
NEW YORK (AP) ' Shares of some top biotechnology companies are mixed at 10 a.m.:
